Truist raised the firm’s price target on Cigna (CI) to $320 from $310 and keeps a Buy rating on the shares. While there remains uncertainty around Enhanced Advance Premium Tax Credits, expectations around an extension resolution are low, and the firm’s estimates assume meaningful membership contraction in Marketplace in 2026 across its coverage universe, the analyst tells investors in a research note. Truist sees an attractive Medicare margin recovery opportunity in both Individual and Group given what a conservative utilization assumptions dialed into pricing following several years of strong trend, the attractive MA rate update, and the companies’ focus on margin over growth aided by targeted initiatives including benefit adjustments, pricing and footprint rationalization.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target raised to $305 from $300 at Barclays
- BofA Rolls Out “Top 10 Ideas” for 1Q26 Across Key Sectors
- Buy/Sell: Wall Street’s top 10 stock calls this week
- BofA lays out Top 10 U.S. ideas for Q1
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
